VRAX
Virax Biolabs Group Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$2.54
+0.40%Margins
Gross margin
-1480.5%
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-97.2%
Return on equity
-88.4%
Return on assets
-112.4%
Return on invested capital
0.00x
Asset turnover
-$7.5M
Cash from operations
$8.18
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026